Publications
Specialty
Search
Gastroenterology
09/23/2024
People in rural and impoverished regions have a higher risk of mortality from early-onset colorectal cancer.
First Report Managed Care
09/23/2024
AI has the potential to revolutionize the diagnosis and treatment of rare diseases, but challenges in patient diversity are being addressed through cross-border collaboration and engagement with patient communities.
First Report Managed Care
09/23/2024
A systematic review delves into the inflammatory profile of non-cystic fibrosis bronchiectasis with associated asthma in children, offering insights for improved treatment strategies.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular, EP Lab Digest
09/23/2024
Oregon study suggests placing defibrillation pads in the front, back could improve dire survival rate — less than one in 10 people nationwide.
Oncology
09/23/2024
At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.
Psych Congress Network
09/23/2024
In 2022, 1 in 5 overdose deaths in the United States involved people with mental health disorders (MHD) unrelated to substance use, according to a study published in Morbidity and Mortality Weekly Report.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
09/23/2024
SSCORE Research Registry follows patients with left anterior descending ST-elevation myocardial infarctions (LAD STEMIs).
First Report Managed Care
09/23/2024
A study published in JAMA Network Open examines the impact of long-term acute care hospital closures on care patterns and outcomes for patients requiring mechanical ventilation, revealing changes in discharge patterns and advanced directive decisions without affecting mortality rates.
EMSWorld
09/23/2024
Braun Ambulances is introducing Select by Braun, a new program with pre-selectable customization for customers who desire market-trending features but require shorter lead times and greater cost efficiency.
First Report Managed Care
09/23/2024
Recent data has established enfortumab vedotin (EV) and pembrolizumab (P) as the preferred first-line (1L) treatment option for patients with metastatic urothelial cancer, according to an article in American Society of Clinical Oncology Educational Book.
Rheumatology & Arthritis
09/23/2024
Already approved for plaque psoriasis, bimekizumab is designed to selectively inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F).
First Report Managed Care
09/23/2024
An investigational 4-factor prothrombin complex concentrate (4F-PCC) was hemostatically non-inferior to a licensed control 4F-PCC for the rapid reversal of vitamin K antagonists (VKA) in patients needing urgent surgery, according to study findings published online in JAMA Network Open.
Rheumatology & Arthritis
09/23/2024
The genetic variant NOD2/CARD15 polymorphism appears related to subclinical intestinal inflammation in patients with axial spondyloarthritis.
EMSWorld
09/20/2024
Did you know there’s a valuable resource at your fingertips that is 100% free, can enhance your patient care, and provide crucial support?
Wound Management & Prevention
09/20/2024
Oncology
09/20/2024
The US Food and Drug Administration granted approval to isatuximab with bortezomib, lenalidomide, and dexamethasone for the frontline treatment of patients with multiple myeloma who are not eligible for autologous stem cell transplant.
Vascular Disease Management
09/20/2024
BRAINTREE, Mass., September 17, 2024 -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced that it has successfully reached the midpoint of the ACCESS-PVI pivotal human clinical trial, enrolling and completing the follow up of 50% of the patients participating in the trial to evaluate the LIBERTY® Endovascular Robotic Surgical System. The Company expects to complete enrollment and follow up in the fourth quarter of 2024 and file its 510(k) submission with the U.S.
IO Learning
09/20/2024
The ACCESS-PVI trial of LIBERTY® Endovascular Robotic Surgical System has enrolled and completed follow-up for 50% of patients.
First Report Managed Care
09/20/2024
Explore the groundbreaking advancements in RNA interference (RNAi) therapeutics, with a focus on the 6 US Food and Drug Administration (FDA)-approved small interfering RNA (siRNA) treatments and how they are revolutionizing disease treatment by targeting gene expression at the posttranscriptional level.
Oncology
09/20/2024
The FDA approved amivantamab plus carboplatin and pemetrexed for patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R substitution mutations and disease progression on or following EGFR tyrosine kinase inhibitor treatment.
Reimbursement Library From A to Z
Subscribe and never miss an article!
Today's Wound Clinic Newsletter
